Introduction: Post-cessation weight gain (PCWG) is a major barrier to maintaining abstinence, especially in weight-concerned smokers. Varenicline is the most effective medication for smoking cessation but has minimal impact on PCWG. Lorcaserin is an FDA-approved medication for weight management in overweight or obese patients which also provides a noticeable benefit in treating drug dependence. We hypothesized that combining varenicline with lorcaserin may help prevent PCWG. We conducted an open-label, single arm, Phase II clinical pilot study to obtain preliminary data on the safety and effectiveness of combination varenicline and lorcaserin in preventing PCWG in overweight and obese smokers. Methods: Twenty overweight or obese (body mass index 27-40 kg/m
Introduction
Cigarette smoking and obesity are the two most important preventable causes of morbidity, mortality, and excess health care costs in the United States. 1, 2 Among smokers achieving smoking abstinence, weight gain is common and may be a major factor of smoking relapse. Most post-cessation weight gain (PCWG) occurs in the first 3 months. 3 The availability of pharmacotherapy facilitating smoking abstinence and preventing PCWG may prompt more smokers to make quit attempts, enhance long-term smoking abstinence, and prevent the development of overweight or obesity among former smokers. 4 Some individuals smoke to control body weight. 5, 6 Smokers gain an average of 5-10 pounds in the months following smoking abstinence, 7, 8 with a significant correlation between body weight and smoking dependent severity. 9, 10 The mean weight gain may be as much as 13 pounds at 1 year 11 and 21 pounds over 5 years. 12 Actual weight gain following smoking abstinence has been associated with smoking relapse. 13 In a large population-based study, 52% of the women and 32% of the men with a previous quit attempt reported that weight gain was one of the reasons for relapse to smoking. 14 In previous research involving the prospective evaluation of a large sample of smokers, 47% of female smokers and 22% of male smokers were classified as having weight concerns. 15 Smoking cessation also leads to increases in visceral fat, and visceral fat is a risk factor for adverse health consequences. 16, 17 Varenicline is presently the most efficacious monotherapy for increasing smoking abstinence rates, with proven superiority over bupropion SR 18, 19 and suggested superiority over nicotine replacement therapy. 20 However, varenicline does not have a clinically meaningful effect on preventing PCWG. 21 Combining the beneficial effects of varenicline with a PCWG intervention might have a significant impact on weight-concerned smokers for whom weight gain is a significant risk factor for smoking relapse.
Lorcaserin is a selective 5-HT 2C receptor agonist with a 100-fold selectivity of 5-HT 2C compared to the 5-HT 2B receptor subtype. 22 Activation of the 5-HT 2C receptor subtype in the hypothalamus increases pro-opiomelanocortin production leading to weight loss through satiety. 23 A number of phase III studies have demonstrated the efficacy of lorcaserin for weight loss in overweight and obese individuals. [24] [25] [26] As a result of the significant weight loss in these studies and the favorable side effect profile, lorcaserin was recently approved by the US Food and Drug Administration (FDA) for weight reduction in overweight and obese patients. 27 In addition to the weight benefits lorcaserin has been shown to reduce nicotine self-administration in animal studies. 28, 29 Combining lorcaserin with varenicline for smoking cessation may offer a unique clinical approach to the treatment of weight-concerned cigarette smokers.
We conducted an open-label, single-arm pilot study to obtain preliminary data on the safety and effectiveness of combination varenicline and lorcaserin in preventing PCWG and treating tobacco dependence in overweight and obese smokers.
Methods

Participants
The Mayo Clinic Institutional Review Board reviewed and approved the current pilot study. Subjects were recruited from the community surrounding Mayo Clinic (Rochester, MN) between September 2013 and July 2014. Overweight or obese daily smokers who were interested in stopping cigarette use were recruited through the news media and local advertisements in Rochester, MN. The study was registered with clinicaltrials.gov (NCT02393547).
Subjects were included if they were: ≥18 years and ≤65 years of age; smoked ≥10 cigarettes/day for the past 6 months; had a measured body mass index (BMI) of 27-40 kg/m 2 ; from Olmsted County area; motivated to stop smoking; weight concerned as determined by the Weight Concern Scale (WCS) 15 ; able to participate fully in all aspects of the study; and understood and signed the study informed consent. Subjects were excluded if they had current nonspecific suicidal thoughts or a lifetime history of a suicidal attempt (defined by the Columbia-Suicide Severity Rating Scale [C-SSRS] as a "potentially self-injurious act committed with at least some wish to die, as a result of act.") 30 ; current moderate or severe depression with a score of ≥16 on the Center for Epidemiologic Studies-Depression (CES-D) 31 ; lifetime history of bipolar disorder or schizophrenia; use of antipsychotic medication (past 30 days); use of weight-loss medications (past 30 days) or current participation in a program designed to help with weight loss; self-reported weight fluctuations of 20 pounds or more in the past 6 months; use of any treatments for tobacco dependence within the past 30 days; use of an investigational drug within the past 30 days; recent history (past 3 months) of abuse of or dependence on a substance other than tobacco; current use of medications known to interact with lorcaserin; any medication known to involve the serotonergic neurotransmitter system; uncontrolled hypertension (systolic >160 mm Hg and/or diastolic >100 mm Hg) documented on two separate occasions; clinically significant acute or chronic progressive or unstable medical condition; current use of medications known to interact with varenicline or lorcaserin; another household member/relative participating in the study; known diabetes; a known allergy to varenicline or lorcaserin; or have taken antibiotics within the past 3 months.
All female subjects of childbearing age were required to have a negative pregnancy test prior to drug initiation. In addition, all female subjects were required to use a reliable form of contraception which included oral contraception, diaphragm or condom (with spermicide), intrauterine device, surgical sterilization, or abstinence.
Procedures
The current study included an initial telephone screen and a total of nine subsequent clinic visits in the Mayo Clinic Department of Medicine Clinical Research Office (DOM CRO). After the initial screen, eligible subjects were invited to come to the DOM CRO for potential enrollment. The clinic visits included an information meeting (screening, physician physical exam, and informed consent), baseline visit (screening, baseline measures, and drug dispensing), six biweekly medication phase visits, and a follow-up visit at 26 weeks. A telephone follow-up call was performed 1 week following the medication phase. Subjects were remunerated up to $100 prorated to the number of completed visits. Vitals, including weight and waist circumference (WC) were measured at baseline, at each medication phase visit, and at the final visit at 26 weeks. Study staff was trained how to measure WC and utilized the methods from a previous study. 32 Brief behavioral counseling was performed by DOM CRO staff during the baseline and medication phase visits. From Baseline to Week 12 (7 visits), the brief (10-minute) individual behavioral intervention was focused on stopping smoking using the "Smoke Free and Living It" manual. 33 At baseline, the study assistants completed an additional brief (10-minute) individual behavioral intervention introducing and reviewing the Mayo Clinic "My Weight Solution" manual, a resource used by Mayo Clinic patients to focus on weight issues. At each subsequent visit, the study assistant reviewed any weight issue the subject chose to discuss, based on this manual.
The varenicline used in the present study was provided by Pfizer through an investigator initiated research grant. In open-label fashion, subjects received varenicline and lorcaserin, which were started simultaneously. Varenicline was prescribed at the recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the remaining 11 weeks of treatment. The target quit date was determined to be 1 day after the 1-week dose-escalation treatment (day 8 of therapy). Varenicline was continued for a total of 12 weeks. Lorcaserin was prescribed at the recommended dosage for overweight and obesity of 10 mg twice daily. Lorcaserin was taken in a dose of 10 mg twice a day from baseline to week 12.
Prolonged abstinence was adjudicated if the following criteria were met: (1) Self-reported smoking abstinence since 2 weeks after target quit date; that is, the participant provided a negative response to the question, "Have you used any type of tobacco, even a puff, for 7 consecutive days or at least once each week on 2 consecutive weeks since xx/xx/xxxx?", where xx/xx/xxxx corresponds to the date 2 weeks after the target quit date; (2) Carbon monoxide measurements confirmed smoking abstinence (≤8 ppm) at the visit for which prolonged smoking abstinence was reported. 
Results
Of the 100 subjects who called in response to the advertising, 33 passed the phone screen and attended the consent visit. Of these 33, 20 subjects consented to the study and were enrolled (Table 1) . Of those enrolled, 14 completed the 12-week treatment phase with two dropping due to adverse events (AEs), three had scheduling difficulties, and one was lost to follow-up. A total of six subjects completed the 26-week follow-up visit. The AEs attributed to the study medications (n = 14) were vivid dreams/sleep disturbance/insomnia (n = 5), constipation (n = 3), heartburn (n = 1), nausea (n = 3), headaches (n = 1), dry mouth (n = 1). One serious AE of suicidal ideation was triggered by escalation of marital problems at home and adjudicated not related to the medications. At the end of 12 weeks of treatment, 50% (n = 10) met the criteria for prolonged smoking abstinence. At the end of the 26-week trial 30% (n = 6) met the criteria for prolonged smoking abstinence.
Of those who met criteria for prolonged abstinence at 12 weeks (n = 10), weight gain compared to baseline was +1.1 ± 3.9 kg (90% CI; −0.9, +3.1) (Figure 1 ), change in BMI (kg/m 2 ) was +0.3 ± 1.3 kg/ m 2 (90% CI; −0.3, +1.0), and change in WC (cm) was +0.2 ± 6.0 (90% CI;−2.9, +3.4). Of those who met criteria for prolonged abstinence at 26 weeks (n = 6), weight gain compared to baseline was +6.4 ± 10 kg (90% CI; −0.3, +13.1), change in BMI (kg/m 2 ) was +1.9 ± 3.0 kg/m 2 (90% CI; −0.1, +3.9), and change in WC (cm) was +2.2 ± 8.3(90% CI; −3.4, +7.9).
Discussion
Our pilot study provides evidence of the potential usefulness of combination varenicline and lorcaserin for prevention of PCWG in overweight and obese smokers attempting to quit smoking. Combination therapy was well tolerated with few side effects. The PCWG at 12 weeks was comparable to a recent large prospective trial of combination varenicline and bupropion (1.1 kg). 34 In contrast to this previous study which did not focus on a specific BMI, we enrolled overweight or obese subjects (BMI 27-40 kg/m 2 ).
At 26 weeks the PCWG was +6.4 ± 10 kg and change in WC was +2.2 ± 8.3 compared to PCWG of +1.1 ± 3.9 kg and change in WC +0.2 ± 6.0 at 12 weeks. The PCWG of +1.1 ± 3.9 kg while on lorcaserin (12 weeks) was lower than a recent meta-analysis (4.23 kg 95% CI 3.69-4.77) found for abstinent smokers at 12 weeks. 3 AEs of the combination of varenicline and lorcaserin were minimal. The present study is the first published study to evaluate PCWG and visceral fat accumulation, through the measurement of WC, using lorcaserin and supports the further evaluation of lorcaserin monotherapy and combination therapy for smoking cessation and prevention of PCWG.
Lorcaserin has been evaluated as monotherapy for smoking cessation in a large multicenter, double blind randomized control trial sponsored by industry (unpublished). 35 A total of 603 smokers were randomized to: (1) lorcaserin 10 mg/day; (2) lorcaserin 10 mg twice a day; (3) or placebo. The primary endpoint was carbon monoxide-confirmed continuous smoking abstinence rate for weeks 9-12. The primary endpoint was achieved in 5.6% of smokers in the placebo group, 8.7% in the once daily dose group, and 15.3% in the twice per daily dose group. The odds ratio for the twice per daily lorcaserin group compared to placebo was 3.02 (95% CI 1.47, 6.22, p = .003). This odds ratio is comparable to that observed in the pivotal varenicline trials compared to placebo (3.85, 95% CI 2.69-5.50, p < .001) and bupropion SR compared to placebo (1.90, 95% CI 1.38-2.62, p < .001). 18 Weight gain was −0.01 kg in placebo compared to −0.98 kg in the lorcaserin twice a day group.
There are a number of limitations of the current study that need to be acknowledged. This is a pilot study with limited sample size, with no comparison arm. Results from this pilot should be interpreted within the context of these limitations.
Lorcaserin appears to hold potential promise as a monotherapy for smoking cessation. In the current pilot study, our evaluation suggests that combining varenicline with lorcaserin appears to be safe and holds potential to improve smoking cessation rates and prevent PCWG and visceral fat accumulation. 
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